Estimated reading time: 6 minutes Key Takeaways Analysts’ average price target of US$204.33 signals ~7.5 % upside, yet forecasts range from US$160 to US$240. Valuations blend discounted cash-flow and peer multiples …
Latest in Trading News
-
-
Estimated reading time: 6 minutes Key Takeaways Consensus estimates suggest an 11.3 % revenue drop and 23 % EPS decline. Investors want fresh guidance on deliveries, margins, and robotaxi progress. Wide analyst price …
-
Estimated reading time: 4 minutes Key Takeaways The Dow slips 19.12 points to 44,323.07, a dip of less than 0.1 percent. Investors pause ahead of a pivotal Federal Reserve policy statement …
-
Estimated reading time: 6 minutes Key Takeaways Average 30-year fixed mortgage now sits at 6.75 %, compared with sub-4 % levels in early 2022. Rates have hovered in a tight 6.7-6.8 % band for …
-
Estimated reading time: 4 minutes Key Takeaways Trump Media & Technology Group now holds approximately two-thirds of its liquid reserves in Bitcoin. The company has launched a $2.5 billion programme dedicated …
-
Estimated reading time: 4 minutes Key Takeaways Oppenheimer initiates “Outperform” coverage on Affirm with an £80 price target. Affirm shows rapid revenue growth and expanding gross merchandise volume. Data-driven underwriting and …
-
Estimated reading time: 4 minutes Key Takeaways The Dow Jones Industrial Average (DJIA) eked out a 0.10 per cent gain, closing at 44,387.56. Weekly trading range highlights increased volatility amid earnings releases. …
-
Estimated reading time: 6 minutes Key Takeaways Hershey shares jumped amid confidence in defensive cash flows, lifting broader consumer-staple sentiment. Rotation into banks helped headline indices erase early losses as …
-
Estimated reading time: 4 minutes Key Takeaways Profit after tax surged to €820 million, more than doubling year-on-year. Average fares jumped 21 %, highlighting robust pricing power. Passenger numbers hit …
-
Estimated reading time: 6 minutes Key Takeaways Sarepta Therapeutics’ shares plunged more than 35 per cent after the FDA requested withdrawal of Elevidys. The gene therapy’s use of the AAVrh74 vector …